- CancerNetwork.com
- CureToday.com
- OncLive.com
- TargetedOnc.com
- Privacy
- Terms & Conditions
- Do Not Sell My Information
© 2022 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
Rudolph Navari on Olanzapine for Preventing Nausea and Vomiting
Rudolph Navari, professor of Medicine at Indiana University School of Medicine - South Bend, discusses the effectiveness of olanzapine (Zyprexa) in preventing nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Rudolph Navari, professor of Medicine at Indiana University School of Medicine — South Bend, discusses the effectiveness of olanzapine (Zyprexa) in preventing nausea and vomiting in patients receiving highly emetogenic chemotherapy.
In a phase III, randomized, double-blind study, Navari added olanzapine to a standard antiemetic regimen and compared it to a placebo with the same antiemetic regimen.
The standard antiemetic regimen supplemented with olanzapine was significantly effective in preventing nausea and vomiting. This was the first study that used nausea as a primary endpoint.
Olanzapine is currently approved by the FDA as an antipsychotic, but not for the prevention of nausea.
Navari says clinical practice should change to use olanzapine with a standard antiemetic regimen for patients receiving highly emetogenic chemotherapy.